Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam for docetaxel-related chemotherapy-induced nausea and vomiting in advanced or recurrent non-small cell lung cancer
jRCTs021260040Recruiting
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lorazepam in chemotherapy-induced nausea and vomiting (CINV). Primary endpoint: Incidence of moderate-to-severe nausea within 5 days after chemotherapy. Started Sep 2026; status: recruiting.
02
Drugs
lorazepam
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCTs021260040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021260040.